Literature DB >> 27510156

[Longterm risk subtotal splenectomy?]

T R Mett1, H Fischer2, J Metzger2.   

Abstract

Mesh:

Year:  2017        PMID: 27510156     DOI: 10.1007/s00104-016-0266-2

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


× No keyword cloud information.
  5 in total

1.  Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis.

Authors:  B Bader-Meunier; F Gauthier; F Archambaud; T Cynober; F Miélot; J P Dommergues; J Warszawski; N Mohandas; G Tchernia
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

Review 2.  The prevention and treatment of bacterial infections in children with asplenia or hyposplenia: practice considerations at the Hospital for Sick Children, Toronto.

Authors:  Victoria E Price; Sanjeev Dutta; Victor S Blanchette; Sheila Butchart; Melanie Kirby; Jacob C Langer; E Lee Ford-Jones
Journal:  Pediatr Blood Cancer       Date:  2006-05-01       Impact factor: 3.167

Review 3.  Overwhelming postsplenectomy infection.

Authors:  A M Lynch; R Kapila
Journal:  Infect Dis Clin North Am       Date:  1996-12       Impact factor: 5.982

4.  Partial splenic embolization in children with hereditary spherocytosis.

Authors:  Barbara Pratl; Martin Benesch; Herwig Lackner; Horst Rupert Portugaller; Bernadette Pusswald; Petra Sovinz; Wolfgang Schwinger; Andrea Moser; Christian Urban
Journal:  Eur J Haematol       Date:  2007-11-19       Impact factor: 2.997

5.  Laparoscopic partial vs total splenectomy in children with hereditary spherocytosis.

Authors:  Julia Morinis; Sanjeev Dutta; Victor Blanchette; Sheila Butchart; Jacob C Langer
Journal:  J Pediatr Surg       Date:  2008-09       Impact factor: 2.545

  5 in total
  1 in total

Review 1.  Splenic infarction after Epstein-Barr virus infection in a patient with hereditary spherocytosis: a case report and literature review.

Authors:  Zhongwu Ma; Zhejin Wang; Xiaodan Zhang; Haibo Yu
Journal:  BMC Surg       Date:  2022-04-09       Impact factor: 2.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.